Methsuximide (Epilepsy = All indications) updated on 04-22-2025

Major congenital malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16584
R69649		 Battino (Methsuximide) (Epilepsy), 2024 Major congenital malformations (MCMs) early pregnancy prospective cohort exposed to other treatment, sick Adjustment: No 31.43 [0.62;1591.57] C 0/1   110/3,584 110 1
ref
S6714
R18987		 Samrén (Methsuximide), 1999 Major congential abnormalities at least 1st trimester retrospective cohort unexposed, disease free Adjustment: No Matched 66.80 [1.30;3423.69] C 0/1   29/2,000 29 1
ref
Total 2 studies 45.77 [2.84;737.32] 139 2
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Battino (Methsuximide) (Epilepsy), 2024Battino, 2024 1 31.43[0.62; 1591.57]110150%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Samrén (Methsuximide), 1999Samrén, 1999 2 66.80[1.30; 3423.69]29150%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 45.77[2.84; 737.32]13920.9500.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Methsuximide) (Epilepsy; 2: Methsuximide;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 45.77[2.84; 737.32]13920%NABattino (Methsuximide) (Epilepsy), 2024 Samrén (Methsuximide), 1999 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 66.80[1.30; 3423.69]291 -NASamrén (Methsuximide), 1999 1 exposed to other treatment, sickexposed to other treatment, sick 31.43[0.62; 1591.57]1101 -NABattino (Methsuximide) (Epilepsy), 2024 1 Tags Adjustment   - No  - No 45.77[2.84; 737.32]13920%NABattino (Methsuximide) (Epilepsy), 2024 Samrén (Methsuximide), 1999 2 MatchedMatched 66.80[1.30; 3423.69]291 -NASamrén (Methsuximide), 1999 1 All studiesAll studies 45.77[2.84; 737.32]13920%NABattino (Methsuximide) (Epilepsy), 2024 Samrén (Methsuximide), 1999 20.51000.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale66.80[1.30; 3423.69]291 -NASamrén (Methsuximide), 1999 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale31.43[0.62; 1591.57]1101 -NABattino (Methsuximide) (Epilepsy), 2024 10.510.01.0